We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently announced the clearance of PMA Supplement for broadening the use of therascreen EGFR RGQ PCR Kit as a companion diagnostic with Pfizer Inc.’s (PFE - Free Report) VIZIMPRO (dacomitinib) by the FDA. It will be used for first-line treatment of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 L858R mutation.
EGFR RGQ PCR Kit in Details
Registered in more than 40 countries, the therascreen EGFR RGQ PCR kit stands approved as a companion diagnostic to guide the use of three FDA-approved therapies, including GILOTRIF (Afatinib) from Boehringer Ingelheim and Iressa (Gefitinib) from AstraZeneca (AZN - Free Report) .
The therascreen EGFR kit also provides laboratories an efficient workflow on the Rotor-Gene Q MDx along with distinguishing a comprehensive panel of EGFR mutations. Notably, Rotor-Gene Q MDx is a real-time PCR module in QIAGEN’s QIAsymphony family of instruments.
Market Potential
Non-small cell lung cancer occurs in around 85% of patients with a lung cancer condition, the leading cause of cancer deaths worldwide. Notably, EGFR mutations leading to growth in cancer cells occur in 10-35% of NSCLC tumors globally. However, EFGR mutations are responsive to treatments, particularly aiming at the the overactive EGFR protein which causes cancer cells to constantly grow and divide.
Progress With Test Menu expansion
QIAGEN is progressing well with the testing menu expansion strategy. Recently, it announced a new development under the company’s long-standing partnership with In Vitro Diagnostics (IVD) player DiaSorin S.p.A. (DSRLF - Free Report) .
This time, the alliance is set to offer a fully-automated CE-Marked testing for latent tuberculosis (TB) infection with QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin LIAISON Platforms.
Furthermore, in May, QIAGEN globally launched DNeasy PowerSoil Pro Kit, the next generation of sample technology for the extraction of fungal and bacterial DNA from a range of soil samples. The next month, the company launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable accurate microbial community profiling from complex microbiome samples.
In April, the company announced the receipt of pre-market approval by the FDA for PartoSure. In the same month, the company launched QIAstat-Dx in Europe following the closure of the recently-announced Stat-Dx acquisition and the completion of defined development activities by Stat-Dx. The company is planning to launch the test in the United States and other geographies in 2019. QIAGEN also launched two novel liquid biopsy panels, AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
QIAGEN N.V. (QGEN - Free Report) recently announced the clearance of PMA Supplement for broadening the use of therascreen EGFR RGQ PCR Kit as a companion diagnostic with Pfizer Inc.’s (PFE - Free Report) VIZIMPRO (dacomitinib) by the FDA. It will be used for first-line treatment of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 L858R mutation.
EGFR RGQ PCR Kit in Details
Registered in more than 40 countries, the therascreen EGFR RGQ PCR kit stands approved as a companion diagnostic to guide the use of three FDA-approved therapies, including GILOTRIF (Afatinib) from Boehringer Ingelheim and Iressa (Gefitinib) from AstraZeneca (AZN - Free Report) .
The therascreen EGFR kit also provides laboratories an efficient workflow on the Rotor-Gene Q MDx along with distinguishing a comprehensive panel of EGFR mutations. Notably, Rotor-Gene Q MDx is a real-time PCR module in QIAGEN’s QIAsymphony family of instruments.
Market Potential
Non-small cell lung cancer occurs in around 85% of patients with a lung cancer condition, the leading cause of cancer deaths worldwide. Notably, EGFR mutations leading to growth in cancer cells occur in 10-35% of NSCLC tumors globally. However, EFGR mutations are responsive to treatments, particularly aiming at the the overactive EGFR protein which causes cancer cells to constantly grow and divide.
Progress With Test Menu expansion
QIAGEN is progressing well with the testing menu expansion strategy. Recently, it announced a new development under the company’s long-standing partnership with In Vitro Diagnostics (IVD) player DiaSorin S.p.A. (DSRLF - Free Report) .
This time, the alliance is set to offer a fully-automated CE-Marked testing for latent tuberculosis (TB) infection with QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin LIAISON Platforms.
Furthermore, in May, QIAGEN globally launched DNeasy PowerSoil Pro Kit, the next generation of sample technology for the extraction of fungal and bacterial DNA from a range of soil samples. The next month, the company launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable accurate microbial community profiling from complex microbiome samples.
In April, the company announced the receipt of pre-market approval by the FDA for PartoSure. In the same month, the company launched QIAstat-Dx in Europe following the closure of the recently-announced Stat-Dx acquisition and the completion of defined development activities by Stat-Dx. The company is planning to launch the test in the United States and other geographies in 2019. QIAGEN also launched two novel liquid biopsy panels, AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>